Ionis Pharma (IONS) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- US stock futures steady as oil jumps to two-week high ahead of key earnings
- Oil prices rise as attacks on Saudi Arabia overshadow Trump's Russian supply announcements
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- Iren shares jump 5% in premarket trade on report of Anthropic AI cloud deal
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Stryker invests $400M in CMR Surgical with option to acquire
- Enovix posts $11M in Q3 revenue, beats guidance by 10%
- Deutsche Bank Upgrades AST Spacemobile (ASTS) to Buy
Ionis Pharmaceuticals (IONS) PT Lifted to $46 at Piper Jaffray
August 10, 2016 7:27 AM EDTPiper Jaffray analyst Joshua Schimmer reiterated an Overweight rating and raised his price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $46.00 (from $36.00) following Q2 earnings and an update on its antisense pipeline.
Schimmer commented, "The company provided some color on nusinersen for the... More



